1. Search Result
Search Result
Results for "

central nervous system agent

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Screening Libraries

7

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0933
    Gadoteridol
    1 Publications Verification

    SQ-32692; Gd-HP-DO3A

    Biochemical Assay Reagents Neurological Disease
    Gadoteridol is a gadolinium-based magnetic resonance imaging (MRI) contrast agent, used in the imaging of the central nervous system .
    Gadoteridol
  • HY-119974

    NSC-253272

    DNA/RNA Synthesis Bacterial Infection Cancer
    Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity .
    Caracemide
  • HY-115139

    Others Neurological Disease
    Fenadiazole acts as a central nervous system agent to manage insomnia and dreaminess .
    Fenadiazole
  • HY-16173

    DM-CHOC-PEN

    DNA Alkylator/Crosslinker Neurological Disease Cancer
    Mipicoledine is a potential neuro-alkylating agent for study of glioblastoma and metastatic cancers involving the central nervous system .
    Mipicoledine
  • HY-B0933A

    SQ-32692 pentahydrate; Gd-HP-DO3A pentahydrate

    Biochemical Assay Reagents Neurological Disease
    Gadoteridol pentahydrate is a gadolinium-based magnetic resonance imaging (MRI) contrast agent, used in the imaging of the central nervous system .
    Gadoteridol pentahydrate
  • HY-B0933R

    Biochemical Assay Reagents Neurological Disease
    Gadoteridol (Standard) is the analytical standard of Gadoteridol. This product is intended for research and analytical applications. Gadoteridol is a gadolinium-based magnetic resonance imaging (MRI) contrast agent, used in the imaging of the central nervous system .
    Gadoteridol (Standard)
  • HY-163629

    Others Cancer
    Anticancer agent 224 (Compound 16) is an anticancer agent that can effectively inhibit the growth of central nervous system (CNS), kidney and breast cancer cell, with a GI50 value ranging from 0.6 to 12.8 μM .
    Anticancer agent 224
  • HY-124382

    TRP Channel Neurological Disease
    AS1928370 is a novel and central nervous system (CNS) penetrant TRPV1 antagonist and can prevent ligand-induced activation in vivo. AS1928370 is a promising agent for neuropathic pain treatment research .
    AS1928370
  • HY-121670

    Others Neurological Disease
    Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan
  • HY-121670A

    Others Neurological Disease
    Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan hydrochloride
  • HY-108335

    619C89; BW 619C89

    Sodium Channel Calcium Channel Neurological Disease
    Sipatrigine (619C89), a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has the potential in the study for focal cerebral ischemia and stroke .
    Sipatrigine
  • HY-149980

    Parasite Infection
    DCN-83, an anti-leishmania agent, is most potent against the amastigote form with an IC50 of 0.71 μM. DCN-83 has the potential to cross the blood-brain barrier and central nervous system .
    DCN-83
  • HY-117471

    Others Neurological Disease
    Antiarrhythmic agent-3 is an antiarrhythmic drug with the activity of enhancing antiarrhythmic efficacy and improving inhibition index. The antiarrhythmic effect of antiarrhythmic agent-3 is related to its hydrophobicity (log P). The central nervous system toxicity of antiarrhythmic agent-3 is related to the combined effect of its hydrophobicity and acid constant (pKa) .
    Antiarrhythmic agent-3
  • HY-107790

    DNA/RNA Synthesis Neurological Disease
    5-Methoxyflavone, belonged to Flavonoid family, is a DNA polymerase-beta inhibitor and neuroprotective agent against beta-amyloid toxicity. possess central nervous system (CNS) depressant effect mediated through the ionotropic GABAA receptors.
    5-Methoxyflavone
  • HY-19262

    Dopamine Receptor Neurological Disease Inflammation/Immunology
    TAK-218 is a promising candidate as an agent tor central nervous system trauma and ischemia. TAK-218 exhibits potent scavenging activity and antioxidative activity. TAK-218 also inhibits dopamine release .
    TAK-218
  • HY-B0225
    Methyldopa
    2 Publications Verification

    L-(-)-α-Methyldopa; MK-351

    Adrenergic Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Methyldopa (L-(-)-α-Methyldopa), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .
    Methyldopa
  • HY-B0225A

    L-(-)-α-Methyldopa hydrochloride; MK-351 hydrochloride

    Adrenergic Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrochloride is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .
    Methyldopa hydrochloride
  • HY-B0225B
    Methyldopa hydrate
    2 Publications Verification

    L-(-)-α-Methyldopa hydrate; MK-351 hydrate

    Adrenergic Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrate is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .
    Methyldopa hydrate
  • HY-B0225AS

    L-(-)-α-Methyldopa-d3 hydrochloride; MK-351-d3 hydrochloride

    Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Methyldopa-d3 (hydrochloride) is deuterium labeled Methyldopa (hydrochloride). Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrochloride is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system[1][2].
    Methyldopa-d3 hydrochloride
  • HY-N0035
    Arctigenin
    Maximum Cited Publications
    8 Publications Verification

    (-)-Arctigenin

    MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin
  • HY-B0225BR

    Adrenergic Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Methyldopa (hydrate) (Standard) is the analytical standard of Methyldopa (hydrate). This product is intended for research and analytical applications. Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrate is a proagent and is metabolized (α-Methylepinephrine) in the central nervous system .
    Methyldopa hydrate (Standard)
  • HY-N0035R

    MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin (Standard) is the analytical standard of Arctigenin. This product is intended for research and analytical applications. Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin (Standard)
  • HY-B0971

    Prophenpyridamine maleate; Tripoton maleate; Pheniramine maleate

    Histamine Receptor Apoptosis Inflammation/Immunology Endocrinology
    Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .
    Pheniramine maleate
  • HY-B0971A

    Prophenpyridamine; Tripoton; Pheniramine solution

    Histamine Receptor Apoptosis Inflammation/Immunology Cancer
    Pheniramine (Prophenpyridamine;Tripoton) is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine displays antitumor effect and induces leukemia cells apoptosis. Pheniramine is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .
    Pheniramine
  • HY-B0900
    Anethole
    1 Publications Verification

    Anise camphor; p-Propenylanisole; Isoestragole

    Apoptosis Fungal Bacterial MMP NF-κB Infection Neurological Disease Inflammation/Immunology Cancer
    Anethole is a type of orally active aromatic compound that is widely found in nature and used as a flavoring agent. Anethole possesses anticancer, anti-inflammatory, antioxidant, antibacterial, antifungal, anesthetic, estrogenic, central nervous system depressant, hypnotic, insecticidal, and gastroprotective effects. Anethole can be used in the study of oxidative stress-related skin diseases and prostate cancer .
    Anethole
  • HY-108760

    Gd-DOTA; Magnescope; P-449

    Biochemical Assay Reagents Cardiovascular Disease Others Neurological Disease
    Gadoterate meglumine (Gd-DOTA) is a non-specific paramagnetic gadolinium complex used as a contrast enhancer in magnetic resonance imaging (MRI). Gadoterate meglumine, as a contrast agent in MRI, is able to shorten the longitudinal relaxation time (T1) of tissue, resulting in a brighter signal in MRI images. Gadoterate meglumine can be used for the study of the central nervous system (such as the brain and spinal cord), abdominal, pelvic organs, breast, bone and joint imaging, angiography, and cardiac electrophysiology .
    Gadoterate meglumine
  • HY-B0725
    Doxepin Hydrochloride
    4 Publications Verification

    Histamine Receptor Cytochrome P450 Neurological Disease Cancer
    Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .
    . Doxepin has therapeutic effects in atopic dermatitis,chronic urticarial,can improve cognitive processes, protect central nervous system .
    . Doxepin has also been proposed as a protective factor against oxidative stress .
    .
    Doxepin Hydrochloride
  • HY-B0725R

    Histamine Receptor Cytochrome P450 Neurological Disease Cancer
    Doxepin (Hydrochloride) (Standard) is the analytical standard of Doxepin (Hydrochloride). This product is intended for research and analytical applications. Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .
    . Doxepin has therapeutic effects in atopic dermatitis,chronic urticarial,can improve cognitive processes, protect central nervous system .
    . Doxepin has also been proposed as a protective factor against oxidative stress .
    .
    Doxepin Hydrochloride (Standard)
  • HY-137055

    Others Others
    PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
    PF-3774076

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: